This recorded plenary session explores the evolving understanding of recurrence risk in non-small cell lung cancer (NSCLC) following induction immuno-oncology (IO)–based therapies and surgical resection. Expert presenters examine emerging data from landmark clinical trials, the role of minimal residual disease (MRD) dynamics, and evolving strategies for optimizing perioperative treatment and patient outcomes. The program also includes the distinguished David J. Sugarbaker Giant’s Lecture, along with new findings from the AEGEAN, CheckMate 816, and AIM-HIGH trials.

Featured Presentations:
• Welcome
• David J. Sugarbaker Giant’s Lecture: Do Randomized Controlled Trials Change Practice?: A Cautionary Tale
• Associations of Post-surgical MRD Status with Neoadjuvant ctDNA Dynamics, Genomic Mutations, and Clinical Outcomes in Patients with Resectable NSCLC (R-NSCLC) from the Phase 3 AEGEAN Trial
• Overall Survival and Efficacy by Surgical Outcomes with Neoadjuvant Nivolumab + Chemotherapy in Patients with Resectable NSCLC in CheckMate 816
• Minimal Residual Disease Dynamics and Pathological Complete Response in a Phase II Trial of Perioperative Immunochemotherapy for Lung Squamous Cell Carcinoma
• Adjuvant Therapy in High-Risk Stage I NSCLC: The AIM-HIGH Trial
• Locoregional Recurrence Rates Following Neoadjuvant Chemo-IO: Tumor Biology or Suboptimal Surgery?
• Discussion

This session is not eligible for CME credit.